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Epilepsy is one of the most common neurological diseases. It is characterised by recurrent episodes of disturbance in 
movement, sensation and consciousness. With the increased incidence rate of epilepsy, a number of treatment modalities as well 
as formulations are being developed in recent years. In Ayurveda also many formulations are available for the treatment of 
epilepsy. However, there is a search of formulations which can show quick and longstanding efficacy on epilepsy. 
Kousheyashma is a mineral drug used in Ayurveda pharmaceutics. It is yellowish white and is identified as asbestos. 
Magnesium, calcium and silicate are the chief chemical entity of this drug. It is an easily and abundantly available mineral in 
India. The Bhasma is economic as the pharmaceutical processing of it is easy. In the pharmacological and therapeutic properties 
of this drug, it is mentioned that it has anti-epileptic activity. However, there is no substantial evidence to prove the antiepileptic 
activity of Kousheyashma. Hence, the present study was undertaken to experimentally evaluate the efficacy of Kousheyashma 
Bhasma in epilepsy. Antiepileptic activity was evaluated in Swiss albino mice by two methods namely Pentylenetetrazol (PTZ)-
induced seizure method and kindling PTZ-induced seizure method. Mice selected based on exclusion and inclusion criteria 
were randomly allocated into five groups. Mice were subjected to chemo convulsions by injecting PTZ intraperitoneally and 
observed for 35 min to analyse convulsion behaviours. Kousheyashma Bhasma has shown statistically significant results in 
PTZ-induced epileptic symptoms in Swiss albino mice. 
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Kousheyashma is a yellowish-white stone which looks 
like compressed fibers attached to one another1. 
Kousheyashma is enlisted under a separate group called 
sikata varga2. It is a naturally occurring mineral in 
abundance in all parts of India. It is used as an 
ingredient in a few formulations mentioned in books of 
Ayurveda. It is also a drug mentioned in the list of 120 
uparasa in Siddha system of medicine. It is termed as 
Kalnar in Tamil, Kannaram and Hiravi3 in Malayalam, 
Ratinara in Telugu and Kalnaru in Kannada. 
Mineralogical features like hardness, specific gravity 
and appearance suggest that it is a drug resembling 
asbestos. The studies done earlier have proved that it is 
a variety of asbestos exhibiting the property of silicate 
of magnesium and calcium4,5. 
Epilepsy is one of the most common neurological 
diseases and approximately 23.4 million people are 
diagnosed with epilepsy each year globally6. Epilepsy 
is characterized by recurrent episodes of disturbance of 
movement, sensation and consciousness. With the 
increased incidence rate of epilepsy, a number of 
treatment modalities as well as formulations are 
being developed in recent years. In Ayurveda also 
many formulations are available for the treatment 
of epilepsy. 
However, there is a search of formulations which 
show quick and longstanding efficacy on epilepsy. In 
recent books of Rasashastra, it is mentioned that 
Kousheyashma Bhasma has anti-epileptic activity7. The 
present study was conducted to evaluate the efficacy of 
Kousheyashma Bhasma in epilepsy experimentally. 
Methodology 
The study was performed on Swiss albino mice 
weighing 20-40 g. They were found in a zoo attached 
to the SDM Center for Research in Ayurveda and 
Allied Sciences, Udupi, Karnataka. They were 
randomly assigned to five groups of six mice each. 
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Kousheyashma Bhasma was prepared according to 
standard guidelines in the Department of Rasasashtra 
and Bhaishajya Kalpana, Sri Dharmasthala 
Manjunath-eswara College of Ayurveda and Hassan 
Hospital. 
The TED (therapeutic dose) drug test solution was 
prepared by mixing 250 mg Kousheyashma Bhasma,  
10 mL of distilled water with carboxy methylcellulose 
sodium salt (CMC) 50 mg and the same method was 
followed for preparing TED 1/2 - 125 mg and TED  
2-500 mg solution. HD × 0.0026 × 50 kg body 
weight/1000 was calculated on the basis of human 
volume using the Standard conversion method on the 
basis of body mass index8. The dose of diazepam was 
approximately 0.05 mg/100 g body weight of mice. 
Similarly the dose of the aesthetic agent was also 
calculated as 80 mg/kg and 40 mg/kg of the PTZ 
method and the PTZ ignition method, respectively 
(Table 1). 
 
Antiepileptic activity was tested in two different 
ways: 
 
Pentylenetetrazol-induced seizure method 
The animals were given a vehicle, test drugs and a 
reference level to the appropriate groups by oral route 
for 10 consecutive days. On the eleventh day, one hour 
after drug administration, they developed a chemo 
disorder after injecting Pentylenetetrazol (PTZ) at a 
dose of 80 mg/kg. The effect of a different treatment on 
the PTZ seizure profile is described below. Parameters 
such as delayed onset of clonic and tonic tremors, 
recurrence of chronic or tonic convulsions, myoclonic 
fluctuations, death and other abnormal changes in 
behaviour were recorded. Elimination of clonic 
convulsions is considered to be an indication of  
anti-convulsive activity. 
 
Pentylenetetrazol kindling method in mice 
For implantation, Pentylenetetrazol (PTZ) dissolved 
in standard saline and a dose less than 40 mg/kg, 
intraperitoneal was administered daily up to 11 
injections. After each sub-convulsive dose of PTZ, 
mice in different groups were observed for 35 min and 
PTZ-induced seizures were recorded with Fischer and 
Kittner's scoring program (1998)9. 
• Ear and face tingling, nodding of the head; 
• Myoclonic Jerks. 
• Increasing general tremors, climbs, and falls, 
• Clonic-tonic tremor, enlargement of posterior 
tonic organs. 
Measurement levels were calculated for all groups 
after each PTZ injection. Scores from test construction 




At the end of the study the mice were sacrificed 
and the brains were carefully removed, purified and 
transferred to 10% formalin before being analyzed for 
histological examination by taking their stage using 
standard laboratory procedures. The slides with the 
found parts were scanned with a Trinocular Carl Zeiss 
microscope under various magnifications. Changes in 
the structure of histoarchitecture were noted. 
 
Results 
Experimental study was done to evaluate the 
antiepileptic action of Kousheyashma Bhasma using 
two methods, Pentylenetetrazol-induced convulsion 
and kindling Pentylenetetrazol-induced convulsion. 
Observations are listed below (Tables 2-6). 
 
Histopathological study 
Histopathological analysis of section of brain was 
done to evaluate the changes in brain of mice after 
Table 1 — Grouping of animals for the experimental study 
Group I Standard Diazepam orally  
0.05 mg/100 g 
Group II Control Normal control 
Group III Study group TED 250 mg 
Group IV Study Group TED ½ 125 mg 
Group V Study Group TED 2 500 mg 
 
Table 2 — Effect of Kousheyashma Bhasma on Pentylenetetrazol-
induced convulsion 
Groups Latency of onset 
(in sec) 
No of Myoclonic 
convulsions 
No of Clonic 
convulsions 
Control 42.4±9.81 41 ± 13.598 7 ± 0.7071 
Standard 209 01 0 
Ted 85.83± 14.23* 43.8 ± 5.894 2.2 ± 0.3742** 
Tedx2 46.6 ± 7.18 12 ± 3.240* 3.2 ± 0.4899** 
Tedx1/2 41.08 ± 3.69 13.2 ± 1.772 2.4 ± 0.6782** 
Data: MEAN ± SEM, **p<0.01, * p < 0.05 
 
Table 3 — Effect of Kousheyashma Bhasma on Pentylenetetrazol-
induced convulsion (Death and Recovery) 
Groups Recovery (in sec) Death (in sec) 
Control 2663.5 ± 36.50 292.33 ± 25.44 
Standard 2700 ± 0.00 0 
Ted 2581.5 ± 66.43 1210± 644.00** 
Tedx2 0 353.83 ± 82.4 
Tedx1/2 0 416.16 ±63.79 
Data: MEAN ± SEM, **p<0.01, * p < 0.05 




administration of Kousheyashma Bhasma and based 
on results observations are made (Table 7). 
 
Discussion 
Objective of the study was to evaluate the anti-
epileptic action of Kousheyashma Bhasma by two 
methods i.e.; pentylenetetrazol convulsion method 
and kindling convulsion method. Evaluations were 
done by making 5 groups: control, standard, TED 
(therapeutic effective dose), TED ½ and TED 2, 
respectively.  
Pentylenetetrazol (PTZ) is a CNS stimulant that 
acts as epileptogenic causing seizures. Therefore it is 
used as a drug to induce epileptic development in 
experimental model and to spot drugs that will 
manage seizure susceptibleness. As a non-competitive 
GABA (gamma- amino saturated fatty acid) 
antagonist, PTZ is specifically employed in seizure 
assays as a way of assessing the excitability of the 
central system and GABA activity. Kindling could be 
a chronic animal model of brain disorder that has been 
comprehensively studied to grasp the method of 
epileptogenesis and see novel anti-epileptic 
compounds. The impact of test/reference compounds 
may be tested by administering them either before the 
initiation of kindling (pre-kindling phase) or once 
animals are totally ignited (post kindling phase) 10. 
After the observation of both methods  
(general & kindling) including all grades, effects of 
Kousheyashma Bhasma on PTZ-induced convulsions 
are mentioned below based on statistical reports. 
Latency of onset 
Duration of latency of onset of seizures was found 
to be increased in TED and TED 2 groups when 
compared to the control group. The observed increase 
was found to be statistically significant with p value 
<0.05 and non-significant respectively. There was a 
decrease in duration of latency of onset of seizures in 
TED 1/2 group when compared to the control group. 
The observed decrease was found to be statistically 
non-significant (Table 2). Epilepsy is a physical 
condition that occurs due to a sudden, brief change in 
the normal working of brain. At this time, the brain 
cells are unable to function properly and the level of 
consciousness was very poor10. So the increased 
latency of onset of seizures indicates reduced chances 
of getting epilepsy. 
 
Myoclonic convulsion 
There was a decrease in number of myoclonic 
convulsion in TED 2; the observed decrease was 
found to be statistically significant with p value < 
0.05. Increase in number of myoclonic convulsion 
was in TED group when compared to the control 
group. The observed increase was found to be 
statistically non-significant. And there was a decrease 
in number of myoclonic convulsion TED ½ group 
when compared to the control group statistically 
shows non-significant in TED ½ (Table 2). Myoclonic 
seizures are brief, shock-like jerks of a muscle which 
occurs because of rapidly alternating contraction and 
relaxation, jerking or twitching of a muscle11. It is one 
of the major symptoms of epilepsy. Decrease in 
number of myoclonic seizures is a positive indication 
towards efficacy of the study drug.  
 
Clonic convulsion 
Number of clonic convulsions were found to be 
decreased in TED, TED 2 & TED ½ groups when 
compared to the control group. The observed decrease 
was found to be statistically significant with p value 
<0.01. Clonic convulsions occur in epilepsy because 
 
Table 5—Effect of Kousheyashma Bhasma on Pentylenetetrazol-
induced total aggregation kindling convulsion 
Groups Total kindling 
Control 397.8 ± 84.751 
Standard 67.714 ± 12.047 ** 
Ted 50 ± 6.221 ** 
Tedx2 68.2 ± 21.264 ** 
Tedx1/2 62.6 ± 8.238 ** 
Data : MEAN ± SEM, **p<0.01 
 
Table 4 — Effect of Kousheyashma Bhasma on Pentylenetetrazol-induced kindling convulsion 
Groups No of Face twitching / head 
nodding 
No of Myoclonic jerks No of generalized 
clonic convulsions 
No of clonic-tonic convulsions, 
tonic hind limb extensions 
Control 87.8 ± 14.168 313 ± 88.648 6.2 ± 1.241 3.4 ± 0.2449 
Standard 61.428 ± 10.869 6.1428 ±1.223** 0 ±00** 0.1428 ± 0.1429** 
Ted 13 ± 2.302** 37.5 ± 10.115** 2.166 ± 0.6540** 0.5 ± 0.3416** 
Tedx2 7.6 ± 1.208** 66.166 ±20.676** 4.833 ± 0.8724 0.5 ± 0.22** 
Tedx1/2 19.6 ± 4.411** 40.33 ± 9.249** 4.66 ± 1.202 0 ± 00** 
Data: MEAN ± SEM, **p<0.01 
 




of fast stiffening and relaxing of a muscle that 
happens repeatedly. Clonic seizures can start in the 
motor area on one side of the brain. The jerking 
movements would affect just one side or part of the 
body or face11. The significant results suggest that the 
study drug acts on muscles.  
 
Recovery/ Death 
Duration of recovery shows there was a non-
significant result in all groups when compared to the 
control group. Duration of death was increased in 
TED group when compared to the control group. The 
observed increase was found to be statistically 
significant with p value < 0.01. Data shows there was 
increase in duration of death in TED 2 and TED ½ 
group when compared to the control group. The 
observed increase was found to be statistically non-
significant (Table 3).  
 
Face twitching / head nodding 
Number of face twitching / head nodding was 
decreased in TED, TED 2 & TED ½ groups when 
compared to the control group. The observed decrease 
was found to be statistically significant with p value < 
0.01 (Table 4).  
 
Number of clonic-tonic convulsions, tonic hind limb extensions 
Number of clonic-tonic convulsions, tonic hind 
limb extensions shows there was decrease in TED, 
TED 2 & TED ½ groups when compared to the 
control group. The observed decrease was found to be 
statistically significant with p value < 0.01 (Table 4).  
These show the combined characteristics of tonic and 
clonic seizures. Tonic means stiffening, and clonic 
means rhythmical jerking11. Significant changes in the 
parameter may be considered for the action of study 
drug on muscular skeletal and neurological symptoms. It 
is pertinent to note that the better results were seen in  
10-20 min suggesting the bioavailability or 
concentration with which the medicine acts.  
 
Number of total aggregation kindling convulsion 
The total number of combined comorbidities shows 
a decrease in the TED, TED 2 & TED groups when 
compared to the control group. The decrease was 
found to be statistically significant in the value of  
p <0.01 (Table 5). 
 
Histopathological changes 
In the cerebrum, all doses of treatment showed 
fewer destructive changes while compared to the 
control group. Positive changes indicate the protective 
effect of Kousheyashma Bhasma on cerebrum tissue. 
In the cerebellum, an increase in Purkinje cell was 
observed in TED & TED 2 compared to the control 
group. The changes may be due to reduced sensory 
transmission that promotes motor control. 
Table 6 — Effect of Kousheyashma Bhasma on Pentylenetetrazol-induced kindling convulsion peak duration (10 to 20 min) 
Groups Face twitching /head 
nodding 
No of Myoclonic jerks No of Generalized 
clonic convulsion 
No of clonic-tonic convulsions, 
tonic hind limb extension 
Control 18.8 ± 3.541 83 ± 31.646 1.2 ±0.7348 0.666 ± 0.2562 
Standard 17.571± 3.760 0.8571 ± 0.2608 ** 0 ± 00 * 0 ±00 
Ted 3 ± 0.3162 ** 2.8 ± 0.3742 ** 0 ± 00 0.1428 ± 0.1429 
Tedx2 0.8± 0.3742** 13 ± 6.017** 0 ± 00 0.1428 ± 0.1429 
Tedx1/2 5.2 ± 1.319 ** 4.2 ± 1.497 ** 0.2 ± 0.2000 0 ± 00 
Data: MEAN ± SEM, **p<0.01, * p < 0.05 
 
Table 7 — Histopathological observations of all groups 
Groups  Changes observed  Remarks 
Ctl All sections showed many degenerated and necrosed neurons in cerebrum and 
hippocampus. Reduced Purkinje cells in cerebellum.  
Moderate to severe degenerative 
features seen 
STD Degenerated neurons have decreased in cerebrum, hippocampus in all sections 
compared with C group. There is an increase in Purkinje cells of cerebellum compared 
to C group.  
No to mild degenerative features. 
Protection seen  
TED Degenerated neurons have decreased in cerebrum, hippocampus in all sections compared 
with C group. There is an increase in Purkinje cells of cerebellum in some sections.  
No to mild degenerative features. Good 
protection seen. 
TEDx2 Degenerated neurons have decreased in cerebrum, hippocampus in all sections 
compared with C group. There is an increase in Purkinje cells of cerebellum in most 
of the sections. 
No to mild degenerative features. Good 
protection seen. 
TED-half Few sections showed more degenerated neurons compared to SDA and TED group. 
There was a reduction in Purkinje cells also. 
Mild to moderate degenerative features. 
Protection seen but less compared with 
TED and SDA groups 
 




While comparing histopathological changes in  
the hippocampus, very few destructive detectors  
were observed in the TED and TED groups  
2. Kousheyashma Bhasma probably reduces cell 
damage due to the presence of essential 
micronutrients such as calcium, iron and magnesium. 
Complete examination of histopathological reports 
in all study drug groups shows a slight change  
in cerebral palsy. The protective and anti-
inflammatory action of Kousheyashma Bhasma can 
be understood in that way. The chances of getting 
epilepsy are reduced by the action of Kousheyashma 
Bhasma by using a defence mechanism for brain cells, 
controlling sudden sensory nerves and reducing 
inflammation. 
 
Possible action mode 
Kousheyashma Bhasma was widely used in the 
treatment of epilepsy, in the ancient tradition and 
Rasashastra's latest textbook is described in the 
treatment of Apasmara. Kousheyashma is 
mineralogically identified as asbestos and studies 
proved that it contains magnesium, silicate, calcium, 
and iron as chemical elements7,8 and Haritamanjari 
(Acalypha indica) used as a bhavana dravya in 
process for bhasma preparations for the antiepileptic 
process12. 
Magnesium is one of the essential nutrients in a 
normal diet. It has been reported that people with 
epilepsy have lower levels of magnesium than people 
without epilepsy13. Removal of Mg can produce 
spontaneous events with a tonic shooting phase and a 
clonic release phase. Such tonic clonic events were 
also recorded from the entorhinal cortex of rat cortico 
hippocampus preparations to the Mg-free per-
perfusate. Magnesium is a potential modem of the 
binding activity due to its ability to counteract 
calcium -flux-stimulating N-methyl-D-aspartate 
(NMDA) receptor. A single dose of Mg organic oral 
salt can prevent NMDA-induced convulsions in mice 
in a dose-dependent manner, similar to NMDA 
receptor blocker14. The presence of 15.30% of 
magnesium in Kousheyashma Bhasma could  
have an impact on colonic and tonic bursts as a  
result of which the results have been observed in the 
present study. 
Calcium is essential for all neurotransmitter release 
and muscle contraction. Given these important 
physiological processes, it seems reasonable to 
assume that hypocalcaemia can lead to a reduction  
in neuromuscular pleasure. However, clinical 
observations often record the role of hypocalcemia in 
the formation of seizures15. 
Iron deficiency (ID) is most prevalent during 
pregnancy and adolescence, which is of great concern 
to them because its impact on the developing nervous 
system is associated with an increased risk of various 
psychiatric disorders later in life. Disruption of the 
balance of interest and inhibition within the brain can 
be detected by the brain's response to taking extreme 
insults16. Presence of 4.45% calcium and presence of 
11.93% of iron in Kousheyashma Bhasma may reduce 
the risk of seizures. 
In this study the preparation of Kousheyashma 
Bhasma haritamanjari (Acalypha indica) was  
used as bhavana dravya in the marana process.  
In a study examining the antiepileptic efficacy of  
this drug, the methanolic extract of Acalypha  
indica leaves was orally administered at doses of  
200 mg / kg Sprague Dawlyrats. Performance  
results showed that the methanolic extract of 
Acalypha indica leaf extract had a potent 
anticonvulsant activity12. This further adds to the 
description of the possible functioning of 
Kousheyashma Bhasma in epilepsy. 
 
Conclusion 
Kousheyashma Bhasma has shown significant 
result on reducing the duration of latency of onset, 
clonic convulsion & duration of death in animal 
model of epilepsy induced by PTZ at a therapeutic 
dose. Study drug has shown reduction in number of 
clonic convulsions, result on myoclonic convulsions 
when consumed in double the therapeutic dose. Study 
drug has shown significant result on almost all 
parameters of epilepsy in kindling method. 
Histopathological reports are suggestive of protective 
action of Kousheyashma Bhasma on brain cells. 
Based on all above observations & results it can be 
concluded that Kousheyashma Bhasma has an 
effective result on epilepsy. 
 
Conflict of Interest 




M M Nidhin: Principal Investigator, data collected 
and documented; G Sharma K: Guide for the study, 
document corrected and edited; S Bhat: Co- Guide for 
the study, statistical analyser; G G Chaitra: review of 
literature. 





1 Joshi D, Text book of rasashastra, 2nded.Trivandrum: 
Ayurveda college publication;1997; p.330 
2 Murthy P H C, Rasashastra the mercurial system,  
1sted. Varanasi: Choukambha Sanskrit Series Office; 2008; 
p.418 
3 Joshi D, Text book of rasashastra, 2nd ed. Trivandrum: 
Ayurveda college publication;1997; p.330 
4 Sharma G K, A Study on the Analytical Evaluation of the 
Mineral Drug Kousheyashma. PG thesis, Govt. Ayurveda 
College Thiruvanathapuram, Kerala University; 2006 
5 Saranya S, Pharamaceutico-Analytical and toxicity study of 
kousheyashma bhasma, Sri Dharmasthala Manjunatheswara 
College of Ayurveda and Hospital Hassan, pg thesis, 
RGUHS Bangalore, Karnataka-2018 
6 http://www.who.int/mediacentre/factsheets/fs999/en/ accessed 
on 14/2/2019, 9.15 am. 
7 Dole A V & Prakash P, A text book of Rasashastra, 
1sted.Varanasi:Chaukhamba Surbharati Prakashan; 2004; p.384 
8 Paget G E & Barnes J M, Evaluation of drug activities, In: 
Pharmacometrics, edited by D R Lawrence & A L 
Bacharach, New York: Academic Press; 1964, p.161. 
9 Zhuk O & Zinkovsky V G, Golovenko N Y, The 
pharmacodynamics of anticonvulsant and subconvulsant 
effects  of  ethanol  in CBA and C57BL/6 mice,  Alcohol  
 
(Fayetteville, N.Y.), 23 (2001) 23-8. 10.1016/S0741-
8329(00)00136-1. 
10 http://www.psychogenics.com/pentylenetetrazole.html assessed 
on 16/02/2019 10 am  
11 Khan Y U, Farooq O, Sharma P & Rafiuddin N, Latency study 
of seizure detection. In: Advances in Computer Science, 
Engineering & Applications. Advances in Intelligent and Soft 
Computing, edited by D Wyld, J Zizka & D Nagamalai, Vol 
166, Springer, Berlin, Heidelberg, 2012. 
12 https://www.epilepsy.com/learn/types-seizures/myoclonic-
seizures assessed on 19/08/19 10 am  
13 Kumar P, Chakrapani P, Arunjyothi B & Rojarani A, Anti-
epileptic activity of Acalypha indica methanolic leaves extract 
with animal experiment, Int J Pharmacogn Phytochem Res, 8 (9) 
(2016) 1560–1565. 
14 Yuen A W C, Sander J W, Society E & Peter C S, Can 
magnesium supplementation reduce seizures in people with 
epilepsy ? A hypothesis, Epilepsy Res, 100 (1–2) (2012) 152–6, 
http://dx.doi.org/10.1016/j.eplepsyres.2012.02.004 
15 Fawcett W J, Haxby E J & Male D A, Magnesium : physiology 
and pharmacology, Br J Anaesth, 83 (2) (1999) 302–20. 
16 Griffiths G M, Calcium in epilepsy, J Neurol Neurosurg 
Psychiatry, S1-15 (57) (1934) 29–38. 
17 Rudy M & Mayer-Proschel M, Iron deficiency affects seizure 
susceptibility in a time- and sex-specific manner, ASN Neuro, 9 
(6) (2017) 1-13. DOI: 10.1177/1759091417746521 
 
 
